



## LEPROT (V-15): sc-103596

### BACKGROUND

Mutation of Ob (Obesity factor), also known as leptin precursor, results in profound obesity and type II diabetes as part of a syndrome that resembles morbid obesity in humans. The Ob gene product may function as a component of a signaling pathway in adipose tissue that functions to regulate body fat. The leptin receptor, designated Ob-R, has been shown to be a single membrane-spanning receptor that most resembles the gp130 signal transducing component of the IL-6, G-CSF and LIF receptor. LEPROT (leptin receptor overlapping transcript), also known as LEPR, VPS55 or OBRGRP, is a 131 amino acid multi-pass membrane protein that is highly expressed in placenta and heart and may play a role in energy homeostasis and body weight control. The gene encoding LEPROT maps to human chromosome 1, which spans 260 million base pairs, contains over 3,000 genes and comprises nearly 8% of the human genome.

### REFERENCES

- White, D.W. and Tartaglia, L.A. 1996. Leptin and OB-R: body weight regulation by a cytokine receptor. *Cytokine Growth Factor Rev.* 7: 303-309.
- Campfield, L.A., Smith, F.J. and Burn, P. 1996. The OB protein (leptin) pathway—a link between adipose tissue mass and central neural networks. *Horm. Metab. Res.* 28: 619-632.
- Friedman, J.M. 1997. Leptin, leptin receptors and the control of body weight. *Eur. J. Med. Res.* 2: 7-13.
- Bailleul, B., Akerblom, I. and Strosberg, A.D. 1997. The leptin receptor promoter controls expression of a second distinct protein. *Nucleic Acids Res.* 25: 2752-2758.
- Sone, M. and Osamura, R.Y. 2001. Leptin and the pituitary. *Pituitary* 4: 15-23.
- Kim, J.H., Ovilo, C., Park, E.W., Fernandez, A., Lee, J.H., Jeon, J.T. and Lee, J.G. 2008. Minimizing a QTL region for intramuscular fat content by characterizing the porcine phosphodiesterase 4B (PDE4B) gene. *BMB Rep.* 41: 466-471.

### CHROMOSOMAL LOCATION

Genetic locus: LEPROT (human) mapping to 1p31.3; Leprot (mouse) mapping to 4 C6.

### STORAGE

Store at 4° C, **\*\*DO NOT FREEZE\*\***. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

### RESEARCH USE

For research use only, not for use in diagnostic procedures.

### PROTOCOLS

See our web site at [www.scbt.com](http://www.scbt.com) or our catalog for detailed protocols and support products.

### SOURCE

LEPROT (V-15) is an affinity purified goat polyclonal antibody raised against a peptide mapping within an internal region of LEPROT of human origin.

### PRODUCT

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-103596 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

### APPLICATIONS

LEPROT (V-15) is recommended for detection of LEPROT of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000); non cross-reactive with LEPROTL1.

Suitable for use as control antibody for LEPROT siRNA (h): sc-88262, LEPROT siRNA (m): sc-105612, LEPROT shRNA Plasmid (h): sc-88262-SH, LEPROT shRNA Plasmid (m): sc-105612-SH, LEPROT shRNA (h) Lentiviral Particles: sc-88262-V and LEPROT shRNA (m) Lentiviral Particles: sc-105612-V.

Molecular Weight of LEPROT: 14 kDa.

### RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.